摘要
目的:分析布地奈德福莫特罗联合孟鲁司特钠治疗支气管哮喘的效果。方法:选取2021年1月—2023年12月邳州东大医院收治的78例支气管哮喘患者为研究对象,采用随机数字表法分为对照组和观察组,各39例。对照组采用布地奈德福莫特罗治疗,观察组采用布地奈德福莫特罗联合孟鲁司特钠治疗。对比两组疗效、咳嗽评分、肺功能及血清学指标。结果:观察组治疗总有效率高于对照组(P=0.023);治疗2周后,两组日间、夜间咳嗽评分降低,观察组低于对照组(P<0.05);治疗2周后,两组第1秒用力呼气容积、用力肺活量水平升高,观察组高于对照组(P<0.05);治疗2周后,两组γ干扰素水平升高,白细胞介素-5、白细胞介素-18水平降低,观察组优于对照组(P<0.05)。结论:布地奈德福莫特罗联合孟鲁司特钠治疗支气管哮喘的效果显著,可降低炎性因子水平,改善咳嗽症状,提高肺功能。
Objective:To analyze the effect of budesonide formoterol combined with montelukast sodium in the treatment of bronchial asthma.Methods:A total of seventy-eight patients with bronchial asthma admitted to Pizhou Dongda Hospital from January 2021 to December 2023 were selected as the study objects,and were divided into control group and observation group by random number table method,with thirty-nine cases in each group.The control group was treated with budesonide formoterol,and the observation group was treated with budesonide formoterol combined with montelukast sodium.The efficacy,cough score,lung function and serological indexes of the two groups were compared.Results:The total effective rate of observation group was higher than that of control group(P=0.023);after 2 weeks of treatment,the daytime and night cough scores of the two groups were decreased,and the observation group was lower than the control group(P<0.05);after 2 weeks of treatment,forced expiratory volume in the first second and forced vital capacity of both groups were increased,and the observation group was higher than the control group(P<0.05);after 2 weeks of treatment,the level of gamma interferon increased and the levels of interleukin-5 and interleukin-18 decreased in both groups,and the observation group was better than the control group(P<0.05).Conclusion:Budesonide formoterol combined with montelukast sodium is effective in the treatment of bronchial asthma,which can reduce the level of inflammatory factors,improve cough symptoms and improve lung function.
作者
冯娜娜
Feng Nana(Department of Respiratory Medicine,Pizhou Dongda Hospital,Pizhou 221300,Jiangsu Province,China)
出处
《中外医药研究》
2024年第25期6-8,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH